Conference Proceedings
Venetoclax (VEN) in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL).
M Davids, A Roberts, J Seymour, W Wierda, S Puvvada, L Gressick, D Alter, L Zhou, S Kim, M Verdugo, J Gerecitano
BRITISH JOURNAL OF HAEMATOLOGY | WILEY | Published : 2018
Grants
Funding Acknowledgements
M. Davids Conflict with: Consultancy or advisory board member to Genentech, Gilead, Janssen, Celgene, InCyte, AbbVie, TG Therapeutics, Pharmacyclics and Infinity Pharmaceuticals; institutional research funding from Pharmacyclics, TG Therapeutics, Genentech and Infinity, A. Roberts Conflict with: Research funding from AbbVie and Genentech; Employee of Walter and Eliza Hall Institute of Medical Research which receives milestone payments related to venetoclax, J. Seymour Conflict with: Research funding from AbbVie and Genentech; Consultant and advisory board member to Roche and Genentech, W. Wierda Conflict with: Research funding from AbbVie and Genentech, S. Puvvada Conflict with: Advisory Board Member to AbbVie, Seattle Genetics, and Pharmacyclics; Institutional research funding from AbbVie, Genentech, Seattle Genetics, Takeda, Spectrum and Janssen; Speakers bureau for Gilead, L. Gressick Conflict with: AbbVie employee and may own stock, D. Alter Conflict with: AbbVie employee and may own stock, L. Zhou Conflict with: AbbVie employee and may own stock, S. Kim Conflict with: AbbVie employee and may own stock, M. Verdugo Conflict with: AbbVie employee and may own stock, J. Gerecitano Conflict with: Consultant and advisory board member to Genentech, AbbVie, Samus Therapeutics, Bayer, Gilead, Incyte and Orexo.